Profile data is unavailable for this security.
About the company
Charles River Laboratories International, Inc. provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and academic institutions around the globe accelerate their research and drug development efforts. The Company's Research Models and Services segment is comprised of three businesses that provide foundational tools that enables its clients to discover new molecules: Research Models, Research Model Services, and Cell Solutions. Its Discovery and Safety Assessment segment provides regulated and non-regulated DSA services to support the research, development, and regulatory-required safety testing of potential new drugs, including therapeutic discovery and optimization plus in vitro and in vivo studies, laboratory support services, and strategic non-clinical consulting and program management to support product development. Its Manufacturing Solutions segment includes Microbial Solutions and Biologics Solutions.
- Revenue in USD (TTM)4.11bn
- Net income in USD438.82m
- Incorporated1994
- Employees20.00k
- LocationCharles River Laboratories International Inc251 Ballardvale StWILMINGTON 01887United StatesUSA
- Phone+1 (781) 222-6000
- Fax+1 (978) 988-5665
- Websitehttps://www.criver.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Exelixis Inc | 1.85bn | 205.05m | 6.45bn | 1.31k | 34.26 | 3.07 | 28.02 | 3.49 | 0.6466 | 0.6466 | 5.84 | 7.21 | 0.621 | 3.12 | 7.78 | 1,409,653.00 | 6.90 | 8.86 | 7.82 | 9.91 | 95.70 | 96.30 | 11.10 | 15.43 | 3.41 | -- | 0.00 | 0.00 | 13.60 | 16.47 | 13.98 | -21.34 | 3.98 | -- |
| Halozyme Therapeutics, Inc. | 862.99m | 318.80m | 6.53bn | 373.00 | 21.22 | 36.69 | 16.29 | 7.57 | 2.42 | 2.42 | 6.54 | 1.40 | 0.4874 | 1.34 | 4.42 | 2,313,644.00 | 18.01 | 18.22 | 19.22 | 21.97 | 78.50 | 79.05 | 36.94 | 39.36 | 5.36 | 966.62 | 0.8941 | 0.00 | 25.62 | 40.43 | 39.31 | -- | 26.82 | -- |
| Ionis Pharmaceuticals Inc | 776.62m | -384.77m | 6.59bn | 927.00 | -- | 22.20 | -- | 8.48 | -2.67 | -2.67 | 5.40 | 2.03 | 0.275 | 0.379 | 81.52 | 837,777.80 | -13.62 | -6.30 | -15.20 | -7.44 | 98.72 | 98.75 | -49.54 | -21.23 | 7.28 | -- | 0.8114 | -- | 34.10 | 5.60 | -35.80 | -- | 11.83 | -- |
| Blueprint Medicines Corp | 282.21m | -288.29m | 6.91bn | 645.00 | -- | 22.23 | -- | 24.49 | -4.82 | -4.82 | 4.59 | 4.96 | 0.2499 | 0.3531 | 6.18 | 430,853.40 | -25.53 | -29.92 | -30.68 | -34.06 | 96.97 | -- | -102.15 | -116.65 | 3.61 | -23.37 | 0.4352 | -- | 22.22 | 41.14 | 9.06 | -- | 4.85 | -- |
| Cerevel Therapeutics Holdings Inc | 0.00 | -460.47m | 7.51bn | 355.00 | -- | 13.29 | -- | -- | -2.72 | -2.72 | 0.00 | 3.10 | 0.00 | -- | -- | 0.00 | -44.76 | -- | -48.20 | -- | -- | -- | -- | -- | -- | -- | 0.3745 | -- | -- | -- | -23.14 | -- | -- | -- |
| Exact Sciences Corp | 2.53bn | -240.23m | 7.97bn | 6.50k | -- | 2.53 | -- | 3.14 | -1.32 | -1.32 | 13.93 | 17.04 | 0.3998 | 5.28 | 11.96 | 389,975.40 | -3.79 | -9.71 | -4.13 | -10.60 | 73.67 | 74.10 | -9.48 | -28.21 | 1.45 | -- | 0.4323 | -- | 19.93 | 40.63 | 67.26 | -- | -3.71 | -- |
| Legend Biotech Corp (ADR) | 342.80m | -465.95m | 8.16bn | 1.80k | -- | 7.01 | -- | 23.79 | -2.60 | -2.60 | 1.90 | 6.39 | 0.2297 | 9.52 | 203.86 | 190,443.30 | -31.22 | -37.71 | -37.33 | -47.19 | 52.35 | -- | -135.92 | -286.51 | 5.57 | -24.44 | 0.2233 | -- | 143.70 | 42.15 | -16.11 | -- | 1.57 | -- |
| Vaxcyte Inc | 0.00 | -436.82m | 8.27bn | 254.00 | -- | 4.17 | -- | -- | -4.22 | -4.22 | 0.00 | 18.24 | 0.00 | -- | -- | 0.00 | -28.19 | -34.22 | -29.52 | -37.21 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -80.00 | -- | 107.28 | -- |
| Charles River Lbrtrs ntrntl Inc | 4.11bn | 438.82m | 10.38bn | 20.00k | 23.64 | 2.85 | 13.42 | 2.52 | 8.52 | 8.52 | 79.74 | 70.67 | 0.5187 | 8.38 | 5.22 | 205,579.80 | 5.69 | 6.46 | 6.53 | 7.62 | 36.45 | 36.99 | 10.97 | 11.58 | 1.37 | 4.80 | 0.4183 | 0.00 | 3.86 | 12.75 | -2.39 | 16.69 | 17.86 | -- |
| Insmed Inc | 315.49m | -746.89m | 10.52bn | 912.00 | -- | -- | -- | 33.34 | -5.23 | -5.23 | 2.20 | -3.13 | 0.2357 | 0.8971 | 9.32 | 345,936.40 | -55.80 | -40.96 | -72.23 | -46.88 | 78.07 | 77.99 | -236.74 | -212.92 | 1.61 | -16.08 | 1.64 | -- | 24.39 | 98.78 | -55.66 | -- | -2.15 | -- |
| BIO-TECHNE Corp | 1.15bn | 202.97m | 11.23bn | 3.05k | 56.65 | 5.57 | 35.80 | 9.73 | 1.26 | 1.26 | 7.16 | 12.79 | 0.4339 | 2.20 | 5.20 | 378,452.80 | 7.63 | 9.57 | 8.07 | 10.20 | 66.80 | 67.35 | 17.59 | 21.91 | 2.88 | 14.00 | 0.1619 | 24.19 | 2.81 | 12.07 | 4.88 | 25.13 | 12.81 | 0.00 |
| Medpace Holdings Inc | 1.96bn | 312.32m | 12.53bn | 5.80k | 41.21 | 18.62 | 36.87 | 6.38 | 9.81 | 9.81 | 61.73 | 21.72 | 1.23 | -- | 7.31 | 332,680.00 | 19.58 | 13.94 | 46.20 | 23.18 | 27.99 | 28.84 | 15.92 | 15.23 | -- | -- | 0.00 | -- | 29.17 | 21.76 | 15.26 | 31.17 | 17.99 | -- |
| Neurocrine Biosciences, Inc. | 1.98bn | 369.70m | 13.84bn | 1.45k | 37.78 | 5.80 | 35.28 | 6.98 | 3.64 | 3.64 | 19.47 | 23.72 | 0.6797 | 1.10 | 4.71 | 1,415,714.00 | 12.68 | 9.77 | 15.58 | 12.19 | 98.05 | 98.51 | 18.65 | 14.79 | 2.47 | -- | 0.049 | -- | 26.76 | 33.13 | 61.62 | 63.90 | 2.67 | -- |
| United Therapeutics Corporation | 2.50bn | 1.05bn | 14.06bn | 1.17k | 15.00 | 2.63 | 12.72 | 5.63 | 21.13 | 21.13 | 50.24 | 120.76 | 0.3891 | 2.50 | 11.31 | 2,138,956.00 | 16.36 | 10.38 | 18.03 | 11.27 | 88.87 | 91.47 | 42.05 | 29.25 | 3.64 | -- | 0.101 | 0.00 | 20.20 | 7.41 | 35.40 | 10.89 | 4.55 | -- |
Data as of Jul 03 2024. Currency figures normalised to Charles River Laboratories International Inc's reporting currency: US Dollar USD
39.16%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| The Vanguard Group, Inc.as of 31 Mar 2024 | 5.83m | 11.32% |
| BlackRock Fund Advisorsas of 31 Mar 2024 | 3.07m | 5.96% |
| SSgA Funds Management, Inc.as of 31 Mar 2024 | 2.09m | 4.07% |
| Kayne Anderson Rudnick Investment Management LLCas of 31 Mar 2024 | 1.88m | 3.65% |
| ClearBridge Investments LLCas of 31 Mar 2024 | 1.51m | 2.94% |
| T. Rowe Price Associates, Inc. (Investment Management)as of 31 Mar 2024 | 1.25m | 2.43% |
| Geode Capital Management LLCas of 31 Mar 2024 | 1.19m | 2.30% |
| Meritage Group LPas of 31 Mar 2024 | 1.18m | 2.30% |
| Allspring Global Investments LLCas of 31 Mar 2024 | 1.11m | 2.16% |
| BlackRock Advisors LLCas of 31 Mar 2024 | 1.06m | 2.06% |
More ▼
Data from 31 Mar 2024 - 31 Mar 2024Source: FactSet Research Systems Inc.
